Should we use nintedanib as early therapy in patients with SSc-ILD?

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

(2023) Dinesh Khanna et al.   RMD Open

Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study

(2023) Corrado Campochiaro et al.   RMD Open

Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography

(2022) Dinesh Khanna et al.   Journal of Scleroderma and Related Disorders

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

(2022) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management

(2022) Elena De Zorzi et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort

(2022) Elisabetta Zanatta et al.   RHEUMATOLOGY

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON

(2022) Yannick Allanore et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial

(2022) Satoshi Ebata et al.   Lancet Rheumatology

Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from EUSTAR

(2022) Anna-Maria Hoffmann-Vold et al.   CHEST

Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials

(2022) Anna-Maria Hoffmann-Vold et al.   Lancet Rheumatology

Progressive pulmonary fibrosis: an expert group consensus statement

(2022) Sujeet K. Rajan et al.   EUROPEAN RESPIRATORY JOURNAL

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

(2022) Toby M Maher et al.   Lancet Respiratory Medicine

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

(2021) Kristin B Highland et al.   Lancet Respiratory Medicine

Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients

(2021) Yasir Suleman et al.   RHEUMATOLOGY

SYSTEMIC SCLEROSIS‐ASSOCIATED INTERSTITIAL LUNG DISEASE: How to incorporate two Food and Drug Administration‐approved therapies in clinical practice

(2021) Dinesh Khanna et al.   Arthritis & Rheumatology

Nintedanib in patients with systemic sclerosis‐associated interstitial lung disease: subgroup analyses by autoantibody status and skin score

(2021) Masataka Kuwana et al.   Arthritis & Rheumatology

Early Radiographic Progression of Scleroderma

(2021) Elizabeth R. Volkmann et al.   CHEST

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

(2020) James R Seibold et al.   ANNALS OF THE RHEUMATIC DISEASES

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

(2020) Anna-Maria Hoffmann-Vold et al.   ANNALS OF THE RHEUMATIC DISEASES

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

(2020) Paolo Spagnolo et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Dinesh Khanna et al.   Lancet Respiratory Medicine

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort

(2019) Wanlong Wu et al.   ANNALS OF THE RHEUMATIC DISEASES

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

(2019) Oliver Distler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort

(2019) Anna-Maria Hoffmann-Vold et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

(2019) Kevin R. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model

(2018) Wanlong Wu et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy

(2018) Peter M. George et al.   Expert Review of Clinical Immunology

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

(2016) Dinesh Khanna et al.   LANCET

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

(2016) Donald P Tashkin et al.   Lancet Respiratory Medicine

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

(2015) Lutz Wollin et al.   EUROPEAN RESPIRATORY JOURNAL

Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry

(2014) Lorinda Chung et al.   CHEST

Interstitial lung disease in connective tissue disease—mechanisms and management

(2014) Athol U. Wells et al.   Nature Reviews Rheumatology